MedTrace Logo

An Expanded Access Program of Ipilimumab for Patients With Glioblastomas and Gliomas

NCT03460782 · Status: NO_LONGER_AVAILABLE · Type: EXPANDED_ACCESS

Last updated 2019-11-08

No results posted yet for this study

Summary

IPILIMUMAB Extended Access Program for patients who received chemotherapy and / or radiation therapy before the protocol, before or after the operation.

Conditions

Interventions

BIOLOGICAL

Ipilimumab

Each patient receives Ipilimumab in regimen and dose according to the official manufacturer's instructions (IV 1 mg / kg every 6 weeks for maximum of 4 doses). Participation of the patient in the program must necessarily be agreed with the current treatment and contain a written agreement with the attending physician. This program is not covered by health insurance. For patients in the postoperative period to provide a mandatory conclusion of histology and molecular-genetic for the identified mutations and the type of tumor.

Sponsors & Collaborators

  • BioGene Pharmaceutical Inc.

    collaborator UNKNOWN

  • Center Trials & Treatment

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • Albania
  • Bosnia and Herzegovina
  • Bulgaria
  • Croatia
  • Romania
  • Russia
  • Serbia
  • Switzerland

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03460782 on ClinicalTrials.gov